* Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own experiment using appropriate negative and positive controls.
PBS, pH 7.4,
0.09% sodium azide
4° C, do not freeze
Product Specific Information
PA5-16576 targets PDGFR beta in IHC (P) applications and shows reactivity with mouse and Human samples.
The PA5-16576 immunogen is a synthetic peptide derived from near the C-terminus of human PDGFR, beta.
PDGFR (Platelet Derived Growth Factor Receptor) exhibits two different isoforms, alpha and beta coded by two different genes. They possess five immunoglobulin like domains that are involved in ligand binding. Two tyrosine kinase domains are separated by a kinase insert to which PI-3 kinase can bind. PDGF AA can bind autophosphorylate and activate only PDGFR, alpha while PDGF BB can bind and activate to both PDGFR, alpha and beta.
PA5-16576 was used in immunohistochemistry to report a phase 2 clinical trial of imatinib mesylate in the treatment of recurrent nonresectable chondrosarcomas
Cancer. 2011 Feb 15;117(4):826-31. "A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor-? or -?: An Italian Sarcoma Group study."
Author(s): Grignani G, Palmerini E, Stacchiotti S, Boglione A, Ferraresi V, Frustaci S, Comandone A, Casali PG, Ferrari S, Aglietta M
Number of Citations: 2
(See PubMed article )
(This product is for In Vitro experimental use only. Not for resale without express authorization.)